Diffuse scaly erythematous plaques in patient taking poziotinib

Código QR

Diffuse scaly erythematous plaques in patient taking poziotinib

Guardado en:

Detalles Bibliográficos
Autores principales:	Reid Oldenburg, MD, PhD, Maha Albukhari, MBBS, Brianne H. Daniels, DO, Amanda F. Marsch, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	acantholysis EGFR/HER inhibitor papulopustular eruption poziotinib tyrosine kinase inhibitor Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/f597d1d3c59a4de395a4a97f974e6c25
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

SYNTHESIS AND SAR STRATEGY OF THIAZOLIDINEDIONE: A NOVEL APPROACH FOR CANCER TREATMENT
por: Rashid,Mohammad, et al.
Publicado: (2020)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth
por: YingYing He, et al.
Publicado: (2021)

Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs
por: Louise Pinet, et al.
Publicado: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer
por: Basile D, et al.
Publicado: (2021)

Pénfigo vulgar tipo cutáneo: Caso clínico
por: Bello,Cristina, et al.
Publicado: (2013)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
por: Tran PN, et al.
Publicado: (2016)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli,Meysam, et al.
Publicado: (2019)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Michela Verzè, et al.
Publicado: (2021)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors
por: Tarek S. Ibrahim, et al.
Publicado: (2021)

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
por: Mohammed A. S. Abourehab, et al.
Publicado: (2021)

Clinical case of papulo-pustular rosacea
por: Anna L. Evseeva, et al.
Publicado: (2021)

New Multi-Targeted Antiproliferative Agents: Design and Synthesis of IC261-Based Oxindoles as Potential Tubulin, CK1 and EGFR Inhibitors
por: Momen R. Fareed, et al.
Publicado: (2021)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi T, et al.
Publicado: (2020)

Ibrutinib-associated atrial fibrillation treatment with catheter ablation
por: Ridhima Kapoor, MD, et al.
Publicado: (2021)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021)

Targeted Therapies in Cancer: To Be or Not to Be, Selective
por: Skye Montoya, et al.
Publicado: (2021)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Joanne E. Davis, et al.
Publicado: (2021)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Jade Cury-Martins, et al.
Publicado: (2018)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole J, et al.
Publicado: (2016)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Yundeok Kim, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

Antibacterial Profile of a Microbicidal Agent Targeting Tyrosine Phosphatases and Redox Thiols, Novel Drug Targets
por: Kylie White, et al.
Publicado: (2021)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
por: Ana Podolski-Renić, et al.
Publicado: (2021)

Papillomatous Erythematous Plaques of the Scrotum
por: Ambra Di Altobrando, et al.
Publicado: (2019)

Familial benign chronic pemphigus (Hailey-Hailey Disease): use of topical immunomodulators as a modern treatment option
por: Tchernev,Georgi, et al.
Publicado: (2011)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang J, et al.
Publicado: (2021)

The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
por: Katarína Vavrová, et al.
Publicado: (2022)

Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway
por: Yi Yang, et al.
Publicado: (2019)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev B, et al.
Publicado: (2016)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)

Erythematous plaques of the vulvo-perineal region
por: Low Qin Jian, et al.
Publicado: (2021)